Back to Search
Start Over
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
- Source :
- Diabetes & Metabolism Journal, Vol 40, Iss 2, Pp 99-114 (2016)
- Publication Year :
- 2016
- Publisher :
- Korean Diabetes Association, 2016.
-
Abstract
- Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a complex and progressive pathogenesis. The two primary mechanisms of T2DM pathogenesis are pancreatic β-cell dysfunction and insulin resistance. Pancreatic β-cell dysfunction is recognized to be a prerequisite for the development of T2DM. Therapeutic modalities that improve β-cell function are considered critical to T2DM management; however, blood glucose control remains a challenge for many patients due to suboptimal treatment efficacy and the progressive nature of T2DM. Incretin-based therapies are now the most frequently prescribed antidiabetic drugs in Korea. Incretin-based therapies are a favorable class of drugs due to their ability to reduce blood glucose by targeting the incretin hormone system and, most notably, their potential to improve pancreatic β-cell function. This review outlines the current understanding of the incretin hormone system in T2DM and summarizes recent updates on the effect of incretin-based therapies on β-cell function and β-cell mass in animals and humans.
Details
- Language :
- English
- ISSN :
- 22336079 and 22336087
- Volume :
- 40
- Issue :
- 2
- Database :
- Directory of Open Access Journals
- Journal :
- Diabetes & Metabolism Journal
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.b49b2fef811a48688342547b4a96bc81
- Document Type :
- article
- Full Text :
- https://doi.org/10.4093/dmj.2016.40.2.99